Compare JMSB & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMSB | CYPH |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.7M | 321.1M |
| IPO Year | 2022 | 2019 |
| Metric | JMSB | CYPH |
|---|---|---|
| Price | $22.94 | $2.45 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | 247.4K | ★ 11.4M |
| Earning Date | 10-28-2026 | 11-16-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | 24.17 | ★ 103.87 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | $16.55 | N/A |
| Revenue Next Year | $148.88 | $408.92 |
| P/E Ratio | $25.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.82 | $0.49 |
| 52 Week High | $24.26 | $4.19 |
| Indicator | JMSB | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 50.14 |
| Support Level | $22.57 | $0.65 |
| Resistance Level | $24.07 | $3.35 |
| Average True Range (ATR) | 0.50 | 0.40 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 67.16 | 44.35 |
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.